Redox Homeostasis and Oxidative Stress in Schizophrenia: Glutathione-NMDA-Neuroimmune Convergence and a Hypothesis-Generating Iron-Lipid Redox Extension

27/08/2026

AI Summary

Impaired redox adaptation links GSH dysregulation, NMDA receptor hypofunction, parvalbumin interneuron vulnerability, mitochondrial-glial dysfunction and neuroimmune signalling.
Evidence is heterogeneous: peripheral biomarkers vary, brain GSH MRS shows largely null group findings, and treatment effects depend on marker and illness phase.
Iron-lipid redox proposed as conditional extension; studies report reduced or redistributed iron, unvalidated plasma assays, no demonstrated ferroptotic neuronal death, and no validated treatment biomarkers.

AI Summary

This narrative review evaluates the human and mechanistic evidence for impaired redox adaptation as a convergence mechanism linking glutathione (GSH) regulation, N-methyl-D-aspartate receptor hypofunction, parvalbumin-interneuron and perineuronal-net vulnerability, mitochondrial-glial dysfunction, and neuroimmune signalling.

Beyond the established GSH-NMDA-redox-immune models, we integrate iron-lipid redox regulation as a conditional, hypothesis-generating extension and apply a deliberately conservative evidence hierarchy.

Longitudinal, sex-aware, multi-compartment, and challenge-based studies are needed to define meaningful redox subgroups; no redox- or ferroptosis-related biomarker is currently validated to guide treatment selection.

Basic summary

Int J Mol Sci. 2026 Aug 8;27(16):7105. doi: 10.3390/ijms27167105.

ABSTRACT

Schizophrenia is a heterogeneous neurodevelopmental disorder in which genetic liability, developmental exposures, illness stage, treatment, and metabolic or inflammatory comorbidity may shape redox biology. This narrative review evaluates the human and mechanistic evidence for impaired redox adaptation as a convergence mechanism linking glutathione (GSH) regulation, N-methyl-D-aspartate receptor hypofunction, parvalbumin-interneuron and perineuronal-net vulnerability, mitochondrial-glial dysfunction, and neuroimmune signalling. The findings do not support a uniform oxidative abnormality across all patients or compartments: the peripheral biomarkers are heterogeneous, the group-level brain GSH magnetic resonance spectroscopy findings are largely null, and treatment-related changes vary by marker and illness phase. Beyond the established GSH-NMDA-redox-immune models, we integrate iron-lipid redox regulation as a conditional, hypothesis-generating extension and apply a deliberately conservative evidence hierarchy. Human studies more often report a lower peripheral iron and reduced or redistributed brain iron than a uniform iron excess; the plasma signals for predominantly intracellular proteins remain analytically unvalidated, and ferroptotic neuronal death has not been demonstrated. Longitudinal, sex-aware, multi-compartment, and challenge-based studies are needed to define meaningful redox subgroups; no redox- or ferroptosis-related biomarker is currently validated to guide treatment selection.

PMID:42653110 | DOI:10.3390/ijms27167105

Document this CPD